Navigation Links
Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients
Date:4/24/2011

Hamilton, ON (April 24, 2011) An over-the-counter drug used to treat diarrhea combined with minocycline, an antibiotic used to treat bacterial infections, could one day change the lives of those living with cystic fibrosis.

Researchers at McMaster University have discovered this creative approach to tackle antibiotic resistance to bacterial infections, a frequent complication of those with cystic fibrosis. Cystic fibrosis is the most common, fatal genetic disease affecting Canadian children and young adults.

"Antibiotic resistance is having a profound effect on known drugs that are used to treat illness and disease," says researcher Eric Brown, professor and chair of McMaster's Department of Biochemistry and Biomedical Sciences and member of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR).

"Previous advances in treating cystic fibrosis have been in managing infection, but since infectious organisms are increasingly developing resistance to antibiotics, the importance of providing new treatments is more important than ever."

Brown, who made the discovery in collaboration with McMaster researchers Gerry Wright and Brian Coombes, found that the combination of these two drugs inhibits the growth of bacteria after screening a collection of previously approved non-antibiotic drugs within McMaster's Centre for Microbial Chemical Biology.

Their screening revealed that this particular combination using the anti-diarrhea drug loperamide increases the efficacy of the antibiotic minocycline against multidrug resistant P. aeruginosa.

"Typically it takes 13 to 15 years to develop a drug," says Brown. "We think that this approach could cut drug development time in half."

"These exciting research findings hold promise that a new, safer method for treating devastating lung infections in people with cystic fibrosis may be just around the corner," says Maureen Adamson, CEO, Cystic Fibrosis Canada, a charity that partnered with the Canadian Institutes of Health Research to fund the project. "These findings could impact healthcare worldwide as antibiotic resistance is a tremendous threat to many populations."

Wright, scientific director of the IIDR, adds that McMaster is one of the only universities to look at the combination of antibiotic and non-antibiotic drugs in combating bacterial resistance. But he believes this marks the beginning of using combination therapy as a more effective way to treat disease.

"This finding has opened doors to discovering the abilities of drugs when combined," he says. "Not only has antibiotic resistance become a growing threat to managing illness and disease, the use of combination therapy has added benefits. These combinations might be a way to selectively target bacteria and combat disease and leave so-called "good bacteria" intact to do other things. In effect you use fewer antibiotics to get the same effect."


'/>"/>

Contact: Laura Thompson
lthomp@mcmaster.ca
905-525-9140, ext. 22196
McMaster University
Source:Eurekalert

Related biology news :

1. Killing drug-resistant melanoma requires combination therapy
2. Combination therapy reduced HER2-positive breast cancers
3. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
4. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
5. Grape news: New treatment combination safe alternative to sulfur dioxide
6. Study: Grass, fungus combination affects ecology
7. Investigators identify cleat/natural grass combination may be less likely to result in ACL injury
8. Diabetes drug kills cancer stem cells in combination treatment in mice
9. Old stain in a new combination
10. Novel therapy improves immune function in teen with rare disease
11. Umbilical cord blood-derived stem cells studied for lupus therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... , February 4, 2016 --> ... SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of 2014. ... to SEK 517.6 M (loss: 30.0). Earnings per share increased ... was SEK 537.4 M (neg: 74.7). , ... Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/3/2016)... , Feb. 3, 2016 Vigilant Solutions announces ... Department in Missouri solved two ... reader (LPR) data from Vigilant Solutions. Brian ... in which the victim was walking out of a convenience store and witnessed ... next to his vehicle, striking his vehicle and leaving ...
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
Breaking Biology News(10 mins):
(Date:2/10/2016)...  Matchbook, Inc., a company specializing in procurement ... announced today the appointment of Jim Shuman ... nearly 25 years of experience in supply chain, ... two decades in executive level roles as the ... and, most recently headed global logistics and procurement ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor ... expecting to fill more than 100 tables for its annual event, which will ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare ... training and support program, Sonalink™ remote monitoring. The inaugural launch of this new ... February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert at SonaCare ...
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse announced ... On Azure, Arvados provides capabilities for managing and processing genomic and health data ... from major institutions collecting and analyzing genomic data,” said Adam Berrey chief executive ...
Breaking Biology Technology: